Changes in Beneficial Ownership · 4
Boundless Bio, Inc.
BOLDNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-10262026_081059.xml
Filing details
- Report period
- 2026-10-22
- Issuer
- Boundless Bio, Inc.
- Issuer CIK
- 0001782303
- Trading symbol
- BOLD
Reporting owner 1
- Name
- TANG KEVIN
- Reporting owner CIK
- 0001178579
- Relationship
- 10% owner
- Address
- 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO, CA, 92121
Reporting owner 2
- Name
- TANG CAPITAL MANAGEMENT LLC
- Reporting owner CIK
- 0001232621
- Relationship
- 10% owner
- Address
- 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO, CA, 92121
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | 2026-10-22 | P · Form 4 | 5,800 | A | 2.40[F1] | 2,995,909 | I | See Footnote[F2] |
| Common Stock | 2026-10-23 | P · Form 4 | 6,234 | A | 2.38[F3] | 3,002,143 | I | See Footnote[F2] |
| Common Stock | 2026-10-26 | P · Form 4 | 9,606 | A | 2.38[F4] | 3,011,749 | I | See Footnote[F2] |
Table key
- P · Form 4
- Purchase on the market or privately
- A
- Acquired
- I
- Indirect
Footnotes
- F1
- The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $2.39 to $2.40. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the range set forth in Footnotes 1 and 3 through 4.↩ 1
- F2
- Tang Capital Partners, LP ("TCP") beneficially owns 691,177 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 950,804 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 691,170 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 678,598 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV.↩ 1↩ 2↩ 3
- F3
- These shares were purchased in multiple transactions at prices ranging from $2.36 to $2.40.↩ 1
- F4
- These shares were purchased in multiple transactions at prices ranging from $2.37 to $2.40.↩ 1
Signature 1
- Signed
- Kevin Tang
- Date
- 2026-10-26
Signature 2
- Signed
- Kevin Tang, Manager
- Date
- 2026-10-26
Company context
Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors. For more information, visit https://boundlessbio.com/.